Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Eastern Cooperative Oncology Group
Eli Lilly and Company
Pfizer
Roswell Park Cancer Institute
Vejle Hospital
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Blokhin's Russian Cancer Research Center
MedImmune LLC
Rigshospitalet, Denmark
University of Pennsylvania
Duke University
Kyungpook National University Hospital
Kyungpook National University Hospital
University of Colorado, Denver
National Cancer Institute (NCI)
GlaxoSmithKline
City of Hope Medical Center
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
Seagen Inc.
Bilecik Seyh Edebali Universitesi
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company
Novartis
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Dokuz Eylul University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Seoul National University Hospital
City of Hope Medical Center
AstraZeneca
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Eli Lilly and Company
Mirati Therapeutics Inc.
HUYABIO International, LLC.
HUYABIO International, LLC.
First Affiliated Hospital of Guangxi Medical University
Pennington Biomedical Research Center
Canadian Cancer Trials Group
Boryung Pharmaceutical Co., Ltd
The University of Texas Health Science Center at San Antonio